# Omega-3 Triglyceride Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/omega-3-triglyceride-randomized-trial-evidence-review
Category: evidence-review
Summary: Omega-3 Triglyceride Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are r
Last reviewed: 2026-07-10
Reviewed by: Migaku Evidence Review
# Omega-3 Triglyceride Randomized Trial: What the Evidence Says

## Quick Answer

Omega-3 Triglyceride Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 randomized trial, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Modulation of Inflammatory Indices by Omega‐3 Fatty Acids Supplementation in Hemodialysis: A Clinical Trial Approach | randomized trial | 2 | 2026-04-27 | 10.1111/cts.70531 |
| Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives | narrative review | 3 | 2026-05-12 | 10.3389/fphar.2026.1789019 |

## What The Sources Report

- Chronic kidney disease (CKD) is characterized by persistent abnormalities in the structure, function, or both of the kidneys, and is associated with patients developing systemic complications. [Shafaei Kachaei Hanieh (2026); evidence level 2]
- Post hoc power analysis for CRP and IL-6 outcomes revealed that the study had a power of approximately 62% to detect a moderate effect size (Cohen's d≈0.5), indicating a potential risk of Type II error due to sample size limitations. [Shafaei Kachaei Hanieh (2026); evidence level 2]
- The updated terminology introduces "metabolic dysfunction-associated steatotic liver disease" (MASLD) to replace NAFLD and "metabolic dysfunction-associated steatohepatitis" (MASH) to replace nonalcoholic steatohepatitis. [Tamehri Zadeh Seyed Saeed (2026); evidence level 3]
- According to the new criteria, MASLD is diagnosed in individuals who have hepatic steatosis along with at least one of five cardiometabolic risk factors, provided that no other underlying causes for liver fat accumulation are identified (;). [Tamehri Zadeh Seyed Saeed (2026); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For omega-3 triglyceride randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Shafaei Kachaei Hanieh (2026). Modulation of Inflammatory Indices by Omega‐3 Fatty Acids Supplementation in Hemodialysis: A Clinical Trial Approach. DOI: 10.1111/cts.70531. PMCID: PMC13121090. PMID: 42045798. License: https://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/ This is an open access.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13121090/
- Tamehri Zadeh Seyed Saeed (2026). Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives. DOI: 10.3389/fphar.2026.1789019. PMCID: PMC13201434. PMID: 42206171. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13201434/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.